TRIDENT LIFELINE LIMITED
(Formerly Trident Lifeline Private Limited)

CIN No. : L51909GJ2014PLC078227
GST No. : 24AAECT8906D1ZG

Date: 05.11.2026

BSE Limited **14th Floor, P. J. Towers,** **Dalal Street, Fort,** **Mumbai – 400001.**	**Stock ID: TLL** **Scrip Code: 543616** **ISIN: INE0MKA01014**

SUB: EARNINGS PRESENTATION-Q2 FY27.

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the Half Year ended 30th September 2026. (Q2 FY27).

Kindly take the above on record.

Thanking You,

Yours Faithfully
For **TRIDENT LIFELINE LIMITED**

PATEL SHRAVAN HARIKRISHNABHAI
Digitally signed by PATEL SHRAVAN HARIKRISHNABHAI
Date: 2026.11.05 17:55:22 +05'30'

SHRAVAN H PATEL
MANAGING DIRECTOR
DIN: 08629141

Encl: As Above

Investor Presentation

Trident Lifeline Limited (TLL)

Q2 FY27 EARNINGS UPDATE



Inside this presentation

03 Earnings update

08 About us

11 Our right to win

19 Investment rationale

20 Financial overview



Executive summary – Q2 FY27 *(based on standalone financials)*

Revenue and profitability

Revenue from operations
₹32.7 crores
19% *YoY growth*

Operating profit (EBITDA[1])
₹9.8 crores
53% *YoY growth*

EBITDA margin
29.8%
653 bps *YoY growth*

Profit after tax (PAT)
₹6.6 crores
33% *YoY growth*

Return and capital

Return on equity (ROE)
24.1%
210 bps *YoY growth*

Return on capital employed (ROCE)
27.9%
287 bps *YoY growth*

Net debt to equity
0.3x
vs 0.2x *in FY26*

Current ratio
2.8x
vs 2.1x *in FY26*

Client and people

Manpower
103
21% *YoY growth*

Number of countries served
47
104% *YoY growth*

Number of global registrations[2]
1,128
6% *YoY growth*

Registrations filed
2,582
8% *YoY growth*

1: EBITDA: Earnings before interest, taxes, depreciation and amortization | 2: Excluding India

Executive summary – Q2 FY27 *(based on consolidated financials)*

Revenue and profitability

Revenue from operations	**₹47.1 crores**	50% *YoY growth*
Operating profit (EBITDA[1])	**₹11.3 crores**	65% *YoY growth*
EBITDA margin	**24.1%**	217 bps *YoY growth*
Profit after tax (PAT)	**₹6.6 crores**	30% *YoY growth*

Return and capital

Return on equity (ROE)	**24.9%**	267 bps *YoY growth*
Return on capital employed (ROCE)	**19.4%**	185 bps *YoY growth*
Net debt to equity	**0.7x**	*vs* 0.7x *YoY growth*
Current ratio	**1.8x**	vs 1.6x *in FY26*

Client and people

R&D and F&D investment[2]	**₹0.7 crores**	89% *YoY growth*
Capacity utilization	**46%**	*vs* 32% *in Q2 FY26*
Number of clients	**64**	*vs* 31% *YoY growth*
Product Portfolio	**3,710**	*vs* 3,625 *in FY26*

1: EBITDA: Earnings before interest, taxes, depreciation and amortization | 2. Figures as of H1 FY27

Performance update and management commentary

Management commentary

Our vision has always extended beyond strengthening our core pharmaceutical formulations business. We believe that developing complementary businesses will create additional avenues for growth and enable us to build a more diversified healthcare platform with the potential to create long-term value. Guided by this vision, over the past decade we have consistently invested in manufacturing capabilities, regulatory approvals, infrastructure and new business verticals. These investments have laid the foundation for our current growth trajectory, and as our businesses scale and operational capabilities strengthen, we are beginning to realize the potential of the platform we have built.

As we enter the next phase, our priority is to translate these capabilities into sustained business growth. This will require continued focus on execution, expanding our market presence, strengthening our product portfolio and improving operational efficiencies. As our newer business verticals progress beyond their initial development and incubation stages, we expect their contribution to our consolidated performance to increase meaningfully over time.

Looking ahead, our aspiration remains to **triple our consolidated business over the next three years.** Achieving this ambition will depend on our ability to scale our business verticals successfully, execute our plans with discipline and allocate capital prudently. We remain committed to pursuing sustainable growth while creating enduring value for our shareholders over the long term.



Hardik Desai, Chairman

Performance update and management commentary

Management commentary

Q2 FY27 has been encouraging for Trident Lifeline Limited, reflecting strong business growth, improved profitability, and continued progress towards our long-term strategic objectives.

Our performance is supported by progress in product registrations, expansion into new markets, additions to our product portfolio, contributions from subsidiaries, and improving utilisation of our existing manufacturing capacities. We are also progressing with the commissioning of our parenterals facility, which is expected to be commissioned after Diwali, subject to operational readiness. This will strengthen our manufacturing capabilities and support our future growth plans. The proposed preferential issue will further strengthen our financial resources. The proceeds will support the Company's strategic priorities and provide a foundation for the next phase of expansion.


During the H2 FY27, our focus will remain on improving capacity utilisation, accelerating execution, expanding our product and market presence, strengthening subsidiary performance, and maintaining financial discipline. Looking ahead, we remain committed to our ambition of tripling our consolidated business over the next three years. With our expanding platform, stronger execution capabilities, and disciplined approach to growth, we believe Trident Lifeline is well positioned to create sustainable long-term value for its shareholders.




Ashish Bafna, Executive Director and CFO

Revenue split across segments – Q2 FY27 *(based on consolidated financials)*


Tablets




Capsules




Medical Devices




Others[1]



Total



Revenue contribution (%)



1: Others include syrups, suspensions, dry powder bottles, ointments


Building a global healthcare platform

Trident at a glance

- Established in 2014 as an export-focused pharmaceutical company, building a scalable global healthcare platform
- Diversified portfolio spanning pharmaceuticals, nutraceuticals, herbals, injectables, personal care, and medical devices
- Hybrid manufacturing model combining strategic partnerships with integrated manufacturing capabilities to enhance scalability and supply reliability
- Integrated WHO-GMP compliant manufacturing platform with scalable capabilities across oral solids, injectables, liquids, and medical devices

The integrated trident ecosystem

Building a diversified manufacturing platform across formulations and medical devices



5	10+	80 crs.	46%	4	47.1 crs.	24.1%
Business verticals	Years of experience	Intrinsic value of registrations	Capacity utilization	Manufacturing facilities	Q2 FY27 revenue	Q2 FY27 EBITDA margin

We partner with distributors for market access while serving as their dedicated manufacturing and supply partner

An integrated model creating value across the pharmaceutical value chain

OPERATIONAL VALUE CHAIN

Procurement

- Trusted indigenous sourcing ensuring quality and cost efficiency

Manufacturing

- WHO-GMP compliant manufacturing with scalable operations

Exports

- Strong presence across regulated and emerging markets

ENABLERS CREATING VALUE

Regulatory and registration

- Country-specific regulatory approvals enabling market access and product launches

Sales and marketing

- Distributor-led marketing model with dedicated manufacturing support

Distribution and patient reach

- Robust distribution network enhancing product availability and market penetration

Our operational excellence and strategic enablers create a self-reinforcing cycle of growth

Consolidated manufacturing capacity (in million) / month[1]

Tablets	120
Capsules	120
Dry powder bottles	3
Ointments	3
Liquid bottles	3
Injectables	10

Registration → Market Access → Sales and Distribution → Integrated Demand → Quality Delivery → Cash Generation → Long-term Investment

1: Capacity utilization is based on two-shift operations

Building a global pharmaceutical platform


2015 - 2016
Company formation
- Beginning of operations
- Strategic alliance for manufacturing
- Export to Africa

2021 - 2022
Market expansion
- Plant approvals
- Export to Latin and CIS countries
- Listing on BSE SME
- Incorporated TNS Pharma Private Limited

2024
Strategic growth
- Commercial operation of TNS
- Incorporated TLL Wellness Limited[1]
- Presence in 30 countries

2025
Operational scale
- Commercial operation of TLL Liquid Facility
- Incorporated TLL Parenterals Limited
- Acquired Trident Mediquip Limited
- Launched cosmetic range under the brand name "YES"
- Strategic alliance with NIPER – Ahmedabad
- Presence in 43 countries

2026
Building future pipeline
- Commercial implementation of TLL Parenterals Injectible facility
- Planning underway for TLL Cefa Facility
- Planning underway for launch of nutraceutical product range
- Acquisition of 50,000 sq. meters of land
- Presence in 46 countries



1: Erstwhile TLL Herbal Limited

Diverse product categories delivering broad therapeutic coverage globally

Product categories

Oral Solids
Tablet, Capsule, Dry powder

Liquids
Syrups, Suspension

Injectables
Ampules, Vials

Ointments & Topicals
Cream, Gel, Ointment,

Medical Devices & Surgical
IV Cannula , IFG Set

Therapeutic excellence

*A/ = Anti

- A/ Bacterial
- A/ Diabetic
- Dental Range
- A/ Lipidemic Drug
- A/ Diarrheal
- A/ Parasitic
- Multivitamins
- A/ Hypertensive Drugs
- A/ Protozoal
- A/ Fungal
- Multiminerals
- Proton Pump Inhibitor
- A/ Malarial
- A/ Histamine
- Nutraceuticals
- NSAIDs

Portfolio Highlights

3,710+
PRODUCTS IN PORTFOLIO

6
DOSAGE FORMS

350+
PRODUCTS WITH IPR

Patient-centric
DELIVERING QUALITY HEALTHCARE SOLUTIONS

A strong registration base is a high-barrier asset that creates a compounding engine for long-term value

Registration platform


1.5 – 3 years
Typical gestation period per registration

$5,000
Estimated cost per global registration

$1,000
Estimated cost per Indian registration

Intrinsic value of registrations stands at ~₹80 crore

Our compounding growth engine



1 Registrations
Build a broad and strong registration base

2 Market access
Unlock opportunities across regulated and emerging markets

3 Revenue growth
Launch more products and expand customer reach

4 Cash generation
Strengthen cash flows and financial flexibility

Value created

Access to new markets
Open doors to new geographies and customer segments

Stronger competitive moat
Time and cost create high barriers for competitors

Expanding revenue opportunities
Multiple products, markets and therapies drive sustained growth

Registrations are **long-term commercial assets** that generate recurring revenue across multiple years and markets

Key driver in creating innovative, market-ready solutions

End-to-end development capabilities

Provide :

- Formulation development
- Process development
- Analytical development

Dedicated R&D and F&D team

Focused on:

- New formulation development
- Global product support
- Portfolio enhancement through dosage innovation


State-of-the-art R&D and F&D infrastructure

Supported by experienced formulation experts.

Core capabilities:

- Formulation design and optimization
- Feasibility and cost assessment
- Reformulation and dosage enhancement
- Customer- and market-driven development

R&D and F&D Investment (₹ crore)



Key value proposition

F&D and R&D team evaluates, develops and commercializes products across markets





Our **in-house R&D and F&D capabilities deliver innovative formulations** aligned with market requirements and long-term growth

Building manufacturing capabilities behind validated global demand

Traditional pharma model

- Factory built before demand exists
- Heavy upfront capital commitment
- Customer sought after setup
- Long investment-to-revenue timeline
- Risk of idle capacity
- Delayed return on capital

Trident demand-led integration model (the engines)

Regulatory

- Global product registrations
- Regulatory filings
- Multi-market regulatory approvals

Demand

- Export demand generation
- Customer engagement expansion
- Distributor network strengthening

Market presence

- Industry credibility building
- Brand positioning enhancement
- Global market visibility

Manufacturing

- Integrated manufacturing
- Brownfield expansion
- Backward integration

Promoter-led Deal closure

Validated demand → integrated capacity → sustainable growth

- **Deep promoter involvement**
- **Faster decision making**
- **Higher conversion opportunities**
- **Accelerated customer acquisition**

Demand-led strategy drives registrations, customer growth, and manufacturing scale with reduced risk

Accreditation from regulatory authorities

Experienced leadership driving growth, governance and long-term value creation



Mr. Hardik Jigishkumar Desai

Chairman

- Over 24 years of experience in the industry
- Instrumental in shaping the company's growth trajectory through leadership and vision
- Responsible for overall management of the company
- Provides leadership and strategic direction across the company's operations



Mr. Shravan Harikrishna Patel

Managing Director

- 8 years of experience in the pharmaceutical industry
- Oversees the company's procurement function
- Drives efficiency and innovation in procurement operations
- Ensures a robust supply chain aligned with market requirements



Mr. Ashish Bafna

Executive Director & CFO

- Fellow Chartered Accountant with over 27 years of experience in finance and accounting
- Holds DISA and CAAT diplomas from ICAI; proficient in SAP (FI–CO module)
- Registered insolvency professional with the IBBI



Ms. Rupaben Chetan Jariwala

Whole-Time Director

- Bachelor of commerce graduate with 7 years of experience in pharmaceutical business administration
- Actively engaged in operations, contributing insights that support organisational growth



Ms. Maniya Hardik Desai

Chief Operating Officer

- 8 years of experience in the pharmaceutical industry
- Contributes to strategic decision-making and governance
- Provides insights into industry trends, regulatory developments, and market dynamics
- Supports long-term business objectives through strategic guidance and governance

Each member of the management team oversees clearly defined functional responsibilities and operates with independent decision-making authority within their respective domain, fostering a professional, accountable, and institution-driven governance framework

Diverse independent board strengthens governance and strategic oversight



Dr. Mishal Shailesh Patel

Independent Director

- Consultant pediatric surgeon with over 15+ years of medical experience
- Holds MBBS, MS, MCh (Gold Medalist), and MRCS (Edinburgh) qualifications
- Provides valuable healthcare insights to Board deliberations.
- Supports strategic decision-making and corporate governance



Ms. Falguni Bhavesh Jariwala

Independent Director

- Serves as Admin Manager and CAS Coordinator at Fountainhead School, Surat
- Holds a Bachelor of Home Science degree from SNDT University, Mumbai
- Brings over 18 years of experience in administration and education
- Contributes diverse perspectives to Board discussions and governance



Ms. Smita Kiran Davda

Independent Director

- Chartered Accountant.
- Brings over 23 years of experience in banking and financial services
- Expertise in banking, finance, risk management, and governance
- Held senior leadership roles at Yes Bank
- Expertise in financial strategy, compliance, and stakeholder value creation



Mr. Sachin Bhandari


Independent Director

- Qualified with an MBA and B.Com
- Brings over 25 years of experience in the pharmaceutical industry
- Expertise in quality systems, regulatory compliance, digital transformation, and risk management
- Leadership experience across UCB Pharma, Boehringer Ingelheim, Sun Pharma, Reckitt Benckiser, and GSK

Each independent director contributes extensive experience and objective oversight, fostering transparency, accountability, and robust governance to support sustainable value creation

Built presence across multiple emerging markets, creating a foundation for scalable growth

Our geographic presence



Europe

Establishing presence and building growth opportunities I Presence across **1** country

CIS

Deepening institutional reach and commercial partnerships I Presence across **7** countries

Africa

Establishing and scaling presence across key regulated and semi-regulated markets I Presence across **17** countries

Latin America


Strengthening portfolio depth and distributor relationships I Presence across **9** countries

Asia

Expanding registrations across high-growth emerging markets I Presence across **13** countries

A diversified international platform with increasing product penetration across **high-growth emerging markets**

Share of global registrations by region



47

Countries present globally

1,128

Global product registrations

2,582

Global registrations filed

Building a larger, more profitable global pharmaceutical platform

Why we believe growth can sustain

Larger registration pipeline
- Supports future launches and revenue growth

Portfolio expansion
- Drives retention, cross-selling and growth

Manufacturing platform
- Improves reliability, control and operating leverage

Focus on high opportunity areas
- Leveraging off-patent molecules and high-growth therapeutics

Commercial expansion
- Expands market reach through strong partnerships

Capital-Efficient model
- Capital efficient approach in select areas with focus on ROCE improvements

Recurring customer relationships
- Drives repeat business and revenue stability

Scalable operating platform
- Supports sustainable growth and operating leverage

Main board migration
- Enhances market visibility, liquidity and investor reach

Value creation framework

1. Registrations
2. Product approvals
3. Product launches
4. Revenue growth
5. Manufacturing utilization
6. Margin expansion
7. Cash generation
8. Reinvestment into growth

2,582
Registrations under approval

47
Countries served

300-400
New registrations added annually

Integrated
Manufacturing strategy

Current investments in registrations, market access, sales infrastructure, and manufacturing are expected to drive multi-year **revenue growth, operating leverage, margin expansion,** and **sustainable value creation**

Income Statement *(based on standalone financials)*

All currencies is in ₹ crores, unless otherwise mentioned

Particulars	Q2 FY27	Q2 FY26	YoY change	Q1 FY27	QoQ change	Q4 FY26	Q3 FY26	FY26
Revenue from operations	32.7	27.4	19%	26.8	22%	32.0	23.7	101.9
Cost of materials consumed	18.9	16.0	17%	15.8	20%	21.9	14.1	62.3
Employee benefits expense	1.5	0.9	61%	1.0	54%	1.2	0.8	3.8
Other expenses	2.5	4.1	(38%)	2.8	(10%)	2.1	2.5	11.5
EBITDA	**9.8**	**6.4**	**53%**	**7.2**	**35%**	**6.7**	**6.3**	**24.3**
EBITDA margin	**29.8%**	**23.3%**	**653 bps**	**26.9%**	**290 bps**	**21.1%**	**26.5%**	**23.9%**
Other income	0.9	1.1	(16%)	0.5	76%	1.6	0.9	4.2
Depreciation and amortization	0.6	0.6	(4%)	0.7	(18%)	0.0	0.7	1.9
Finance cost	1.3	0.4	216%	0.5	169%	0.4	0.5	1.7
Profit before tax	**8.8**	**6.5**	**36%**	**6.6**	**34%**	**8.0**	**5.9**	**25.0**
Tax expense	2.2	1.5	44%	1.5	44%	2.3	1.9	6.9
Profit after tax	**6.6**	**4.9**	**31%**	**5.0**	**31%**	**5.7**	**4.0**	**18.1**
PAT margin	**20.1%**	**18.0%**	**209 bps**	**18.7%**	**141 bps**	**17.7%**	**17.0%**	**17.8%**

Cash flow Statement *(based on standalone financials)*

All currencies is in ₹ crores, unless otherwise mentioned

Particulars	FY24	FY25	FY26	H1 FY27
Net Cash from Operating Activities (A)	0.9	2.0	7.9	6.3
Net Cash from Investing Activities (B)	-11.0	-7.9	-20.1	-10.9
Net Cash from Financing Activities (C)	2.4	2.0	14.1	4.6
Net Increase / (Decrease) in Cash (A+B+C)	**-7.8**	**-3.9**	**2.0**	**-0.1**

Balance Sheet *(based on standalone financials)*

All currencies is in ₹ crores, unless otherwise mentioned

Equity and Liabilities	FY24	FY25	FY26	H1 FY27
Share capital	11.5	11.5	11.9	12.0
Reserves & surplus	41.2	54.2	83.4	95.6
Minority interest	-	-	-	-
Total shareholders equity	**52.7**	**65.7**	**99.1**	**111.2**
Share application money pending allotment	-	-	3.7	3.6
Non- current liabilities				
Borrowings	3.7	6.5	6.8	21.4
Provisions	-	-	-	0.0
Deferred tax liabilities	-	0.5	0.9	0.9
Total non-current liabilities	**3.7**	**6.9**	**7.7**	**22.3**
Current liabilities:				
Short term borrowings	2.6	8.5	17.9	21.0
Trade payables	7.6	9.6	26.0	13.2
Other current liabilities	5.0	4.3	2.8	1.4
Provisions	1.7	2.6	5.7	5.4
Total current liabilities	**16.9**	**25.1**	**52.4**	**41.1**
Total liabilities	**20.6**	**32.1**	**60.1**	**63.4**
Total equity and liabilities	**73.2**	**97.8**	**159.2**	**174.6**

Assets	FY24	FY25	FY26	H1 FY27
Non-current assets:				
Tangible assets	3.3	8.0	18.3	18.1
Intangible assets(incl. goodwill)	4.3	6.8	10.3	11.6
Capital work in progress	4.0	0.5	-	1.0
Non-current investment	4.4	12.5	19.7	27.9
Deferred tax assets	0.1	0.0	0.0	0.0
Loans & advances	4.0	0.8	0.8	1.0
Other non-current assets	-	-	-	0.0
Total non-current assets	**20.3**	**28.7**	**49.1**	**59.6**
Current assets:				
Inventories	11.1	16.6	23.2	24.8
Trade receivables	13.8	20.4	49.3	43.0
Cash and cash equivalents	6.0	2.1	4.1	4.0
Short term loans and advances	18.6	25.3	30.9	40.8
Other current assets	3.6	4.8	2.5	2.3
Total current assets	**53.0**	**69.1**	**110.1**	**115.0**
Total assets	**73.2**	**97.8**	**159.2**	**174.6**

Income Statement *(based on consolidated financials)*

All currencies is in ₹ crores, unless otherwise mentioned

Particulars	Q2 FY27	Q2 FY26	YoY change	Q1 FY27	QoQ change	Q4 FY26	Q3 FY26	FY26
Revenue from operations	47.1	31.3	50%	33.7	40%	50.0	25.7	129.0
Cost of materials consumed	27.4	18.1	51%	20.3	35%	33.4	15.1	76.5
Employee benefits expense	3.1	3.4	(9%)	1.7	82%	2.2	2.5	10.8
Other expenses	5.3	3.0	79%	3.2	64%	3.4	3.0	13.7
EBITDA	**11.3**	**6.9**	**65%**	**8.5**	**33%**	**11.0**	**5.1**	**28.1**
EBITDA margin	**24.1%**	**21.9%**	**217 bps**	**25.3%**	**(120 bps)**	**22.0%**	**19.8%**	**21.8%**
Other income	1.0	1.7	(42%)	0.6	69%	1.6	4.6	9.3
Depreciation and amortization	1.6	0.9	71%	1.6	(4%)	1.2	2.5	6.1
Finance cost	1.9	1.0	95%	0.9	125%	0.8	1.2	4.1
Profit before tax	**8.8**	**6.6**	**33%**	**6.6**	**33%**	**10.6**	**6.0**	**27.2**
Tax expense	2.2	1.5	44%	1.5	44%	3.8	1.4	7.9
Profit after tax	**6.6**	**5.1**	**30%**	**5.1**	**30%**	**6.8**	**4.6**	**19.3**
PAT margin	**14.0%**	**16.2%**	**(224 bps)**	**15.0%**	**(102 bps)**	**13.6%**	**18.1%**	**15.0%**

Cash flow Statement *(based on consolidated financials)*

All currencies is in ₹ crores, unless otherwise mentioned

Particulars	FY24	FY25	FY26	H1 FY27
Net Cash from Operating Activities (A)	2.2	- 4.0	4.7	11.5
Net Cash from Investing Activities (B)	-20.4	-13.8	-36.6	-16.7
Net Cash from Financing Activities (C)	11.0	13.5	33.7	5.2
Net Increase / (Decrease) in Cash (A+B+C)	**-7.1**	**-4.3**	**1.8**	**0.0**

Balance Sheet *(based on consolidated financials)*

All currencies is in ₹ crores, unless otherwise mentioned

Equity and Liabilities	FY24	FY25	FY26	H1 FY27
Share capital	11.5	11.5	11.9	12.0
Reserves & surplus	40.4	53.0	84.7	98.3
Minority interest	1.1	5.2	7.5	8.5
Total shareholders equity	**53.0**	**69.6**	**104.2**	**118.7**
Share application money pending allotment	1.0	-	3.7	3.6
Non- current liabilities				
Borrowings	12.8	32.3	40.0	54.5
Provisions	0.1	0.1	0.1	0.1
Deferred tax liabilities	0.0	0.5	0.9	0.9
Total non-current liabilities	**12.9**	**32.8**	**41.0**	**55.5**
Current liabilities:				
Short term borrowings	5.6	21.8	33.0	35.5
Trade payables	7.5	14.8	38.4	23.1
Other current liabilities	5.4	14.0	9.1	9.7
Provisions	1.7	3.0	7.4	7.2
Total current liabilities	**20.3**	**53.6**	**87.9**	**75.4**
Total liabilities	**33.1**	**86.4**	**128.9**	**130.9**
Total equity and liabilities	**87.1**	**156.0**	**236.8**	**253.2**

Assets	FY24	FY25	FY26	H1 FY27
Non-current assets:				
Tangible assets	16.3	35.0	42.6	42.4
Intangible assets(incl. goodwill)	4.6	9.0	18.2	21.3
Capital work in progress	4.0	1.6	17.5	21.0
Non-current investment	3.8	10.7	8.2	15.9
Deferred tax assets	0.1	2.4	3.0	3.0
Loans & advances	4.3	1.4	1.7	1.9
Other non-current assets	2.0	5.6	6.2	8.5
Total non-current assets	**35.1**	**65.6**	**97.3**	**114.0**
Current assets:				
Inventories	12.6	28.2	36.4	44.3
Trade receivables	13.4	27.7	73.7	61.2
Cash and cash equivalents	6.7	2.5	4.2	4.2
Short term loans and advances	13.4	20.3	16.6	16.2
Other current assets	5.9	11.7	8.6	13.3
Total current assets	**52.0**	**90.4**	**139.5**	**139.2**
Total assets	**87.1**	**156.0**	**236.8**	**253.2**

Safe harbor statement

This presentation and the accompanying slides (the "Presentation"), which have been prepared by Trident Lifeline Limited (the "Company'), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Certain matters discussed in this Presentation may contain statements regarding the Company's market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and worldwide, competition, the company's ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections. All Maps used in the presentation are not to scale. All data, information, and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

Get in Touch with Us

For further information, please contact:

Nikita Sharma
Company Secretary
compliance@tridentlifeline.com



Our Investor Relations Partner

Atlas Capital
CAPITAL MARKETS & STRATEGIC ADVISORY

Meeting Request

Link

Preet Choradiya
+91 73832 01103
preet@atlascapital.in

Mr. Rutul Shah
+91 82002 47366
rutul@atlascapital.in